Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to -$2.3 million.

  • Lineage Cell Therapeutics' Cash from Investing Activities fell 100.31% to -$12,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 5.98%. This contributed to the annual value of -$2.3 million for FY2024, which is 104.97% down from last year.
  • Lineage Cell Therapeutics' Cash from Investing Activities amounted to -$2.3 million in FY2024, which was down 104.97% from $46.4 million recorded in FY2023.
  • Lineage Cell Therapeutics' Cash from Investing Activities' 5-year high stood at $46.4 million during FY2023, with a 5-year trough of -$46.2 million in FY2022.
  • Its 3-year average for Cash from Investing Activities is -$672,667, with a median of -$2.3 million in 2024.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 573.67% in 2022, then soared by 200.63% in 2023.
  • Yearly analysis of 5 years shows Lineage Cell Therapeutics' Cash from Investing Activities stood at $13.0 million in 2020, then dropped by 25.26% to $9.7 million in 2021, then slumped by 573.67% to -$46.2 million in 2022, then surged by 200.63% to $46.4 million in 2023, then slumped by 104.97% to -$2.3 million in 2024.